Cardiff Oncology (CRDF) vs LENZ Therapeutics (LENZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 54.6% versus a loss of 92.1%. Over five years, CRDF leads with a -83.1% price change compared with -95.9% for LENZ. LENZ Therapeutics is the larger company by market cap ($114.5 million vs $84.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | LENZ |
|---|---|---|
| Share price | $1.08 | $3.65 |
| Market cap | $84.02M | $114.53M |
| 1-day change | +1.89% | +3.26% |
| YTD return | -61.57% | -77.22% |
| 1-year return | -54.62% | -92.12% |
| 5-year return | -83.13% | -95.93% |
| EPS (TTM) | $-0.60 | $-4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $42.98 |
| 52-week low | $0.76 | $3.35 |
| Distance from 52-week high | -67.37% | -91.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +558.44% |
| Average volume | 1.04M | 824.63K |
| Shares outstanding | 77.80M | 31.42M |
| Employees | 30 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed LENZ by 37.5 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
CRDF vs LENZ FAQ
Which is bigger, Cardiff Oncology or LENZ Therapeutics?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $114.53M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, CRDF or LENZ?
CRDF returned -54.62% over the past 12 months, compared with -92.12% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and LENZ Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.